KR20180063221A - 멜라노코르틴-4 수용체 경로-관련 장애의 치료 방법 - Google Patents

멜라노코르틴-4 수용체 경로-관련 장애의 치료 방법 Download PDF

Info

Publication number
KR20180063221A
KR20180063221A KR1020187012330A KR20187012330A KR20180063221A KR 20180063221 A KR20180063221 A KR 20180063221A KR 1020187012330 A KR1020187012330 A KR 1020187012330A KR 20187012330 A KR20187012330 A KR 20187012330A KR 20180063221 A KR20180063221 A KR 20180063221A
Authority
KR
South Korea
Prior art keywords
subject
mutation
functional
agonist
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020187012330A
Other languages
English (en)
Korean (ko)
Inventor
레오나르두스 에이치.티. 반 데르 플로에그
바르트 헨더슨
피터 쿠넨
Original Assignee
리듬 파마슈티컬즈, 인코포레이티드
샤리떼 우니베지테츠메디친 베를린
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리듬 파마슈티컬즈, 인코포레이티드, 샤리떼 우니베지테츠메디친 베를린 filed Critical 리듬 파마슈티컬즈, 인코포레이티드
Publication of KR20180063221A publication Critical patent/KR20180063221A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187012330A 2015-09-30 2016-09-29 멜라노코르틴-4 수용체 경로-관련 장애의 치료 방법 Pending KR20180063221A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
US62/235,003 2015-09-30
PCT/US2016/054457 WO2017059076A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Publications (1)

Publication Number Publication Date
KR20180063221A true KR20180063221A (ko) 2018-06-11

Family

ID=57138146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012330A Pending KR20180063221A (ko) 2015-09-30 2016-09-29 멜라노코르틴-4 수용체 경로-관련 장애의 치료 방법

Country Status (20)

Country Link
US (5) US20180215790A1 (enExample)
EP (4) EP4029513A1 (enExample)
JP (7) JP7051106B2 (enExample)
KR (1) KR20180063221A (enExample)
CN (2) CN108601816A (enExample)
AU (6) AU2016330773A1 (enExample)
BR (1) BR112018006674A2 (enExample)
CA (2) CA3000670A1 (enExample)
DK (1) DK3356386T3 (enExample)
ES (1) ES2985734T3 (enExample)
FI (1) FI3356386T3 (enExample)
HK (1) HK1259424A1 (enExample)
IL (3) IL299541A (enExample)
MA (2) MA43038A (enExample)
MX (2) MX2018003983A (enExample)
PL (1) PL3356386T3 (enExample)
PT (1) PT3356386T (enExample)
SG (1) SG10202101510XA (enExample)
WO (2) WO2017059076A1 (enExample)
ZA (1) ZA201802704B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539551T3 (pl) 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
FI3356386T3 (fi) * 2015-09-30 2024-05-16 Rhythm Pharmaceuticals Inc Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
AR113885A1 (es) 2017-11-15 2020-06-24 Rhythm Pharmaceuticals Inc Formulaciones de péptidos de liberación sostenida
US20210052551A1 (en) 2018-02-20 2021-02-25 Charite - Universitatsmedizin Berlin MC4R Agonist Efficacy in Subjects with MC4R Deficiencies and Impaired NFAT Signaling
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
CA3181543A1 (en) * 2020-05-04 2021-11-11 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
TW202228760A (zh) * 2020-09-24 2022-08-01 美商律森製藥股份有限公司 治療黑素皮質素-4受體路徑相關病症之方法
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
KR20250127061A (ko) * 2022-11-18 2025-08-26 리듬 파마슈티컬즈, 인코포레이티드 Mc4r 작용제를 이용한 비만 치료 방법
WO2024155828A1 (en) * 2023-01-18 2024-07-25 Loma Linda University Health Uses of aminopyridines in the management of weight and satiety
CN117143183B (zh) * 2023-08-25 2024-08-16 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
EP1594986B1 (de) 2003-02-19 2011-07-13 Universität Duisburg-Essen Verwendung einer genveränderung im humanen gnas-gen zur vorhersage von erkrankungsrisiken, krankheitsverläufen und zur vorhersage des ansprechens auf krankheitstherapien
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CA2530024A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
EP2236151B1 (en) 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
EP2106406A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087189A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
RU2450017C2 (ru) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
AR072072A1 (es) 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
CA2727317C (en) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AU2009278838B2 (en) 2008-08-06 2013-07-25 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
JP2012501334A (ja) 2008-08-29 2012-01-19 トランス テック ファーマ，インコーポレイテッド 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
CN102223898A (zh) 2008-11-25 2011-10-19 诺沃—诺迪斯克有限公司 治疗肥胖的肽
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
AU2010279719A1 (en) 2009-08-05 2012-03-01 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
CN102574894A (zh) 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
CN102665401A (zh) * 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
PL3539551T3 (pl) * 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
AU2014227712B2 (en) * 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
FI3356386T3 (fi) * 2015-09-30 2024-05-16 Rhythm Pharmaceuticals Inc Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä

Also Published As

Publication number Publication date
WO2017059076A8 (en) 2018-04-26
EP3356386A1 (en) 2018-08-08
JP2021088611A (ja) 2021-06-10
WO2017059075A1 (en) 2017-04-06
IL289996B1 (en) 2023-03-01
US20180311309A1 (en) 2018-11-01
AU2022279420B2 (en) 2024-09-19
MA43038A (fr) 2018-08-08
CN108431023A (zh) 2018-08-21
US20210169970A1 (en) 2021-06-10
JP2025019234A (ja) 2025-02-06
AU2016330772A1 (en) 2018-04-19
MX2023003358A (es) 2023-03-29
EP3356386B1 (en) 2024-02-14
IL258412A (en) 2018-05-31
ZA201802704B (en) 2024-08-28
IL289996B2 (en) 2023-07-01
CN108601816A (zh) 2018-09-28
IL289996A (en) 2022-03-01
JP2021102650A (ja) 2021-07-15
JP2022173426A (ja) 2022-11-18
IL258412B2 (en) 2023-06-01
DK3356386T3 (da) 2024-05-21
SG10202101510XA (en) 2021-03-30
CA3000673A1 (en) 2017-04-06
ES2985734T3 (es) 2024-11-07
PL3356386T3 (pl) 2024-08-05
PT3356386T (pt) 2024-05-17
US10960046B2 (en) 2021-03-30
BR112018006674A2 (en) 2018-10-09
AU2022279420A1 (en) 2023-01-19
AU2016330773A1 (en) 2018-04-19
AU2023229494A1 (en) 2023-09-28
HK1259424A1 (zh) 2019-11-29
US20250195606A1 (en) 2025-06-19
EP3355905A1 (en) 2018-08-08
JP2018531937A (ja) 2018-11-01
US12263202B2 (en) 2025-04-01
MX2018003983A (es) 2018-11-09
US20220226425A1 (en) 2022-07-21
FI3356386T3 (fi) 2024-05-16
JP7051106B2 (ja) 2022-04-11
WO2017059076A1 (en) 2017-04-06
JP2018531938A (ja) 2018-11-01
EP4360704A3 (en) 2024-07-24
US20180215790A1 (en) 2018-08-02
JP2023078335A (ja) 2023-06-06
EP4029513A1 (en) 2022-07-20
JP6940853B2 (ja) 2021-09-29
CA3000670A1 (en) 2017-04-06
MA43040A (fr) 2018-08-08
AU2024278597A1 (en) 2025-01-16
IL299541A (en) 2023-02-01
EP4360704A2 (en) 2024-05-01
AU2021201448A1 (en) 2021-03-25
CN108431023B (zh) 2022-11-04
JP7752373B2 (ja) 2025-10-10

Similar Documents

Publication Publication Date Title
JP7752373B2 (ja) メラノコルチン４受容体経路関連障害を治療する方法
Ergun-Longmire et al. Growth and growth disorders
US20240058414A1 (en) Methods of treating melanocortin-4 receptor pathway-associated disorders
EP3539551B1 (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
EP3755362B1 (en) Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
KR20250106335A (ko) Mc4r 효능제로 비만을 치료하는 방법
RU2785889C1 (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
HK40077660A (en) Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation
Han et al. Treatments for Rare Forms of Genetic Obesity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P12-X000 Request for amendment of application rejected

St.27 status event code: A-2-2-P10-P12-nap-X000